Marcelo Negrao, MD

Articles by Marcelo Negrao, MD

Dr Negrao on JDQ443 Plus TNO155 in Advanced, KRAS G12C–Mutated Solid Tumors

September 11th 2023

Marcelo Vailati Negrao, MD, discusses efficacy findings from the phase 1b/2 KontRASt-01 trial (NCT04699188) in patients with KRAS G12C–mutated solid tumors.

Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRAS G12C–Mutated Non-Small Cell Lung Cancer Who Have Untreated CNS Metastases

ByMarcelo Negrao, MD

August 18th 2023

Marcelo Negrao, MD, presents key data from the KRYSTAL-1 trial investigating adagrasib in patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC) and untreated central nervous system (CNS) metastases.

Latest Updated Articles

Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRAS G12C–Mutated Non-Small Cell Lung Cancer Who Have Untreated CNS Metastases
Published: August 18th 2023 | Updated:

Marcelo Negrao, MD

Articles by Marcelo Negrao, MD

Dr Negrao on JDQ443 Plus TNO155 in Advanced, KRAS G12C–Mutated Solid Tumors

Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRAS G12C–Mutated Non-Small Cell Lung Cancer Who Have Untreated CNS Metastases

Latest Updated Articles

Trending on OncLive

FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression

Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer

Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma

FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma

Oncology Fellows Presents a New Drug Cheat Sheet for Fellows